MetaCap

Apollomics (APLM) vs Tonix Pharmaceuticals (TNXP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Apollomics (APLM) has outperformed Tonix Pharmaceuticals (TNXP) over the past year, gaining 7.4% versus a loss of 85.2%. Over five years, APLM leads with a -98.4% price change compared with -100.0% for TNXP. Tonix Pharmaceuticals is the larger company by market cap ($46.2 million vs $45.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

APLM+7.43%TNXP-85.22%
+103%+4%-94%
Nov 21, 20251 yearNov 20, 2026
APLM-98.43%TNXP-100.00%
+157%+22%-112%
Nov 22, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

APLM versus TNXP key metrics
MetricAPLMTNXP
Share price$15.54$2.38
Market cap$45.28M$46.25M
1-day change-6.92%-6.67%
YTD return-16.90%-84.76%
1-year return+7.43%-85.22%
5-year return-98.43%-100.00%
EPS (TTM)$-0.25$-12.39
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$13.11M
Revenue growth (YoY)—+29.85%
Net income (latest FY)$-53.86M$-124.02M
Gross margin—49.34%
Operating margin—-959.05%
Net margin—-946.22%
52-week high$28.29$20.56
52-week low$12.58$2.30
Distance from 52-week high-45.09%-88.42%
Analyst consensus—strong_buy
Avg. price target upside—+1769.75%
Average volume11.07K838.83K
Shares outstanding2.91M19.43M
Employees14142
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • APLM has outperformed TNXP by 92.7 percentage points over the past year.

About Apollomics

APLM stock →

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

About Tonix Pharmaceuticals

TNXP stock →

Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia.

Health Care · Biotechnology: Pharmaceutical Preparations · 142 employees

APLM vs TNXP FAQ

Which is bigger, Apollomics or Tonix Pharmaceuticals?

Tonix Pharmaceuticals (TNXP) is larger, with a market capitalization of $46.25M compared with $45.28M for Apollomics (APLM).

Which stock has performed better over the past year, APLM or TNXP?

APLM returned +7.43% over the past 12 months, compared with -85.22% for TNXP (price return, excluding dividends). Past performance does not predict future results.

Are Apollomics and Tonix Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons